Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
| Autor: | D.Th. Sleijfer, J B E Smeets, Hendricus Groen, G de Leede, Z Erjavec, J Nabers, J. W. G. van Putten, P Eppinga |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Deoxycytidine Gastroenterology Antimetabolite TOXICITY CISPLATIN chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans COMBINATION Lung cancer METAANALYSIS Chemotherapy business.industry gemcitabine Regular Article CHEMOTHERAPY medicine.disease epirubicin Gemcitabine Surgery non-small-cell lung cancer Oncology chemistry Quality of Life business Febrile neutropenia medicine.drug Epirubicin |
| Zdroj: | British Jounal of Cancer, 82(4), 806-811. Nature Publishing Group British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1054/bjoc.1999.1003 |
| Popis: | The aim of the study was to evaluate efficacy and tolerance of epirubicin and gemcitabine as first-line chemotherapy in patients with advanced non-small-cell lung cancer. A phase I study was performed with the combination of escalating doses of epirubicin intravenously on day 1 and a fixed dose of gemcitabine on days 1 and 8 of a 21-day cycle. Eighteen patients were included in the phase I part of the study before the maximum tolerated dose was found. Dose-limiting toxicity was febrile neutropenia. The phase II part of the study was continued with epirubicin 100 mg m(-2) on day 1 and gemcitabine 1125 mg m(-2) on days 1 and 8 of a 21-day cycle. Forty-three chemotherapy-naive patients were included. The median age of the patients was 60 years (range 26-75). Most patients (74%) were in stage IV. Granulocytopenia CTC grade 4 occurred in 32.5% and thrombocytopenia grade 4 in 11.6% of cycles. Febrile neutropenia occurred in six patients. Nonhaematological toxicity was mainly mucositis CTC grade 2 and 3 in 35% of patients. The tumour response rate was 49% (95% confidence interval (CI) 35-63%). The median survival time for the patients was 42 weeks (95% Cl 13-69). (C) 2000 Cancer Research campaign. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|